For example, the G-CSF + Plerixafor combination is now considered to be superior to the standard G-CSF mobilization β-in thalassemia [184,185,186,187] and Fanconi Anemia [188], while G-CSF is contraindicated in patients with sickle cell disease and for SCD gene therapy, Plerixafor-mobilized HSCs are harvested [189,190]. This evidence concerns the gene CSF3 and Schnyder corneal dystrophy.